NIFTY 50▲24,834.85
428.75 (1.76%)
SENSEX▲81,332.72
1292.92 (1.62%)
NIFTY BANK▲51,295.95
407.20 (0.80%)
INDIAN RAILWAY FINANCE CORP▼183.44
-0.12 (-0.07%)
TATA MOTORS▲1,118.30
27.35 (2.51%)
TATA STEEL▲162.55
5.16 (3.28%)
TATA POWER▲444.70
21.35 (5.04%)
SUZLON ENERGY▲61.89
0.42 (0.68%)
RAIL VIKAS NIGAM▼552.35
-23.35 (-4.06%)
INDIAN RENEWABLE ENERGY▼258.03
-3.15 (-1.21%)
VODAFONE IDEA▲15.98
0.80 (5.27%)
RELIANCE INDUSTRIES▲3,018.05
33.25 (1.11%)
YES BANK▲24.97
0.35 (1.42%)
ADANI POWER▲712.65
17.45 (2.51%)
NHPC▲104.62
2.66 (2.61%)
STATE BANK OF INDIA▲862.45
13.95 (1.64%)
HDFC BANK▲1,618.15
1.55 (0.10%)
RELIANCE POWER▲29.77
0.08 (0.27%)
JIO FIN SERVICES LTD▲331.90
2.70 (0.82%)
ZOMATO▲224.62
5.31 (2.42%)
ADANI PORT & SEZ▲1,542.75
55.75 (3.75%)
BHARAT ELECTRONICS▲309.90
8.45 (2.80%)
INDIAN RAILWAY TOURISM CORP▲984.15
15.00 (1.55%)
INDIAN OIL CORP▼176.55
-0.30 (-0.17%)
RATTANINDIA POWER▲16.87
0.06 (0.36%)
MRF▲1,38,870.35
1280.25 (0.93%)
ADANI ENTERPRISES▲3,080.50
107.00 (3.60%)
JAIPRAKASH POWER VENTURES▲19.66
0.83 (4.41%)
![stock logo](https://assets.upstox.com/content/assets/images/logos/NSE_EQ|INE495B01038.png)
Suven Life Sciences Share Price
SUVEN
₹147.86+₹7.04 (5.00%) TodayLast updated on 26 Jul, 2024 | 15:56 IST
₹139.66₹147.86
L
H
What’s in news?
Company overview
Financial performance
Market cap
| Open₹141.25 | Close₹140.82 |
Circuit range₹155.25 - ₹140.46 | Day range₹139.66 - ₹147.86 | Year range₹60.75 - ₹147.86 |
Volume8,08,720 | Avg. traded₹146.53 | Revenue (12m)₹12 Crs |
Suven Life SciencesSuven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (?4?2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Suven Life Sciences Key indicators
52 week high₹147.86 | 52 week low₹60.75 | P/E ratio |
P/B ratio11.4 | ROE-0.94% | ROCE-1.03% |
Dividend yield-- | Debt/Equity ratio | EPS-0.37 |
Learn more
Featured in
Investment checklist: (2/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 1 experts in the last 7 days
Fundamentals
Financial ratios
Operating profit margin-83.17% | Net profit margin-68.49% |
ROE-0.94% | ROA-0.89% |
ROCE-1.03% |
Learn more
Suven Life Sciences Share Price history
Day | Open | Close | Day’s change |
---|---|---|---|
Thu, Jul 25 2024 | ₹133.06 | ₹140.82 | |
Wed, Jul 24 2024 | ₹135.49 | ₹134.12 | |
Tue, Jul 23 2024 | ₹133.98 | ₹133.05 | |
Mon, Jul 22 2024 | ₹125.50 | ₹131.73 | |
Fri, Jul 19 2024 | ₹131.50 | ₹125.46 | -4.44% |
Thu, Jul 18 2024 | ₹136.00 | ₹131.29 | -3.01% |
Tue, Jul 16 2024 | ₹132.00 | ₹135.36 | |
Mon, Jul 15 2024 | ₹133.27 | ₹131.85 | -1.07% |
Events
Corporate actions
Rights Issue • 1:2
Ex date 17 Oct 2022
Learn more